血液透析患者动脉粥样硬化事件的预测因素:AURORA 研究的事后分析
AURORA 试验纳入 2773 例血液透析患者,按 SHARP 标准重新裁定动脉粥样硬化终点。平均随访 3.2 年,506 例发生复合动脉粥样硬化事件。年龄、男性、糖尿病、既往心血管病、透析时长、白蛋白、高敏 C 反应蛋白和氧化低密度脂蛋白胆固醇为显著预测因素,而低密度脂蛋白胆固醇和安慰剂/瑞舒伐他汀分组均不能预测结局。
要点
- 平均随访 3.2 年,2773 例血液透析患者中 506 例发生复合动脉粥样硬化事件。
- 白蛋白每升高 1 g/L,风险比为 0.96(95%CI 0.94-0.99)。
- 高敏 C 反应蛋白每升高 1 mg/L 风险比 1.13(95%CI 1.04-1.22),氧化低密度脂蛋白胆固醇每升高 10 U/L 风险比 1.09(95%CI 1.03-1.17)。
核心结论
- 即使采用严格的终点定义,非传统危险因素而非脂质紊乱预测血液透析患者的动脉粥样硬化事件。
- 低密度脂蛋白胆固醇及安慰剂/瑞舒伐他汀分组均不能预测该结局。
研究设计与样本
- AURORA 试验的事后分析,纳入 2773 例血液透析患者。
- 按 SHARP 研究标准重新裁定所有死亡和疑似心肌梗死,以区分动脉粥样硬化性与非动脉粥样硬化性心血管事件。
- 采用逐步 Cox 回归分析识别预测因素。
主要发现
- 平均随访 3.2 年,506 例患者发生新的复合动脉粥样硬化结局。
- 年龄、男性、现患糖尿病、既往心血管病、每周透析时长被选为显著预测因素。
- 基线白蛋白每升高 1 g/L,风险比 0.96(95%CI 0.94-0.99)。
- 高敏 C 反应蛋白每升高 1 mg/L,风险比 1.13(95%CI 1.04-1.22)。
- 氧化低密度脂蛋白胆固醇每升高 10 U/L,风险比 1.09(95%CI 1.03-1.17)。
关键数值与推荐
- 重新裁定的动脉粥样硬化终点包括:非致死性心肌梗死、致死性冠心病、非致死性与致死性非出血性卒中、冠状动脉血运重建术及缺血性肢体病所致死亡中的首次事件。
- 低密度脂蛋白胆固醇未预测结局,安慰剂/瑞舒伐他汀分组亦未预测结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients on haemodialysis (HD) are at high risk for cardiovascular events, but heart failure and sudden death are more common than atherosclerotic events. The A Study to Evaluate the Use of Rosuvastatinin in Subjects on Regular Hemodialysis: An Assessment of Survival and Cardiovascular Events (AURORA) trial was designed to assess the effect of rosuvastatin on myocardial infarction and death from any cardiac cause in 2773 HD patients. We studied predictors of the atherosclerotic cardiovascular events in AURORA. METHODS: We readjudicated all deaths and presumed myocardial infarctions according to the criteria used in the Study of Heart and Renal Protection (SHARP); these were specifically developed to separate atherosclerotic from non-atherosclerotic cardiovascular events. The readjudicated atherosclerotic end point included the first event of the following: non-fatal myocardial infarction, fatal coronary heart disease, non-fatal and fatal non-haemorrhagic stroke, coronary revascularization procedures and death from ischaemic limb disease. Stepwise Cox regression analysis was used to identify the predictors of such events. RESULTS: During a mean follow-up of 3.2 years, 506 patients experienced the new composite atherosclerotic outcome. Age, male sex, prevalent diabetes, prior cardiovascular disease, weekly dialysis duration, baseline albumin [hazard ratio (HR) 0.96; 95% confidence interval (CI) 0.94-0.99 per g/L increase], high-sensitivity C-reactive protein (HR 1.13; 95% CI 1.04-1.22 per mg/L increase) and oxidized low-density lipoprotein (LDL) cholesterol (HR 1.09; 95% CI 1.03-1.17 per 10 U/L increase) were selected as significant predictors in the model. Neither LDL cholesterol nor allocation to placebo/rosuvastatin therapy predicted the outcome. CONCLUSIONS: Even with the use of strict criteria for end point definition, non-traditional risk factors, but not lipid disturbances, predicted atherosclerotic events in HD patients.
引用
- Solbu MD, Mjøen G, Mark PB, et al. Predictors of atherosclerotic events in patients on haemodialysis: post hoc analyses from the AURORA study. Nephrol Dial Transplant. 2018. PMID: 27798199. doi:10.1093/ndt/gfw360
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。